Mix JM, Saraiya M, Thompson TD, et al. - Considering the value of US population-based cancer registries for surveillance of human papillomavirus (HPV) types detected in HPV-associated cancers, researchers herein compared the HPV prevalence among high-grade cervical precancers and invasive cervical cancers before and after HPV vaccine availability using these registries. From 7 central cancer registries in Florida; Hawaii; Iowa; Kentucky; Louisiana; Los Angeles County, California; and Michigan, they identified archived tissue from 2 studies of cervical precancers and invasive cervical cancers diagnosed from 1993-2005 (prevaccine); cases were identified from 3 registries in Iowa, Kentucky, and Louisiana from 2014 through 2015 (postvaccine). Typing of a total of 676 precancers (328 prevaccine and 348 postvaccine) and 1,140 invasive cervical cancers (777 prevaccine and 363 postvaccine) was done. Findings revealed no decrease in vaccine-type prevalence between the 2 studies, which could be explained by the low number of cases and low HPV vaccination coverage among women in the postvaccine study. For evaluating the impact of the HPV vaccine, they suggest monitoring HPV-type prevalence through population-based strategies to remain relevant in future.